Literature DB >> 1379832

Metastatic tumors of the axial spine.

R G Perrin1.   

Abstract

Spinal metastases are the most common tumors of the axial spine. Symptomatic spinal metastases in children and adults differ in a number of respects including culpable primary tumors, the degree of spinal column involvement, surgical strategies, and results of treatment. Magnetic resonance imaging has become the imaging method of choice for spinal tumors. The management of symptomatic spinal metastases is undertaken to relieve pain and to preserve or restore neurologic function. Radiation therapy is generally regarded as the initial treatment of choice. However, there has been a steady evolution in concepts and execution of surgical strategies for spinal secondaries. A prospective, randomized study should be undertaken to clarify the respective roles of therapeutic irradiation and surgery for metastatic tumors of the axial spine.

Entities:  

Mesh:

Year:  1992        PMID: 1379832     DOI: 10.1097/00001622-199206000-00017

Source DB:  PubMed          Journal:  Curr Opin Oncol        ISSN: 1040-8746            Impact factor:   3.645


  4 in total

Review 1.  Surgical indications and prognosis in spinal metastases.

Authors:  K Nanassis; C Alexiadou-Rudolf; J Rudolf; R A Frowein
Journal:  Neurosurg Rev       Date:  1997       Impact factor: 3.042

2.  Spine metastases: are minimally invasive surgical techniques living up to the hype?

Authors:  Fahed Zairi; Marie-Helene Vieillard; Richard Assaker
Journal:  CNS Oncol       Date:  2015-06-22

3.  Minimally invasive treatment of spinal metastases: techniques.

Authors:  Peter S Rose; Michelle J Clarke; Mark B Dekutoski
Journal:  Int J Surg Oncol       Date:  2011-06-28

4.  Survival rate and neurological outcome after operation for advanced spinal metastasis (Tomita's classification > or = type 4).

Authors:  Young Min Kwon; Keun Su Kim; Sung Uk Kuh; Dong Kyu Chin; Byung Ho Jin; Yong Eun Cho
Journal:  Yonsei Med J       Date:  2009-10-21       Impact factor: 2.759

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.